Hepatology International国际肝病学

Hepatology International(英文缩写 HEPATOL INT),ISSN 1936-0533,eISSN 1936-0541,中文译名:国际肝病学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。

发文量统计区间：2025-09-24 至 2026-09-24，按本站收录文献的发表日期统计。

历年影响因子趋势

Hepatology International 最新收录文献

1. JCR分区: Q1 CAS分区: B1 影响因子: 7.8

   1. Dynamic changes in controlled attenuation parameter (CAP) improve prognostic prediction for CHB patients with significant fibrosis and cirrhosis.

   PMID:

   42762383

   作者:

   Xiaowei Ai, Mengyang Zhang, Shuyan Chen, Xinyu Zhao, Jialing Zhou, Tongtong Meng, Bingqiong Wang, Chenglin Sun, Xiao Han, Yankun Gao, Xiaoning Wu, Hong You, Yameng Sun

   期刊:

   Hepatology international PubMed

   DOI:

   10.1007/s12072-026-11145-w

   日期:

   2026-09-19

   The coexistence of hepatic steatosis and chronic hepatitis B (CHB) is becoming increasingly common. Although the controlled attenuation parameter (CAP) has been widely used to quantify hepatic steatos…

   查看详情PubMed 原文记录
2. JCR分区: Q1 CAS分区: B1 影响因子: 7.8

   2. Coronary atherosclerosis across stages of metabolic dysfunction-associated steatotic liver disease: a VCTE-CCTA study.

   PMID:

   42749969

   作者:

   Gediz Dogay Us, Francesco Innocenti, Ozgur Muhammet Koc, Sevval İlke Ebeoglu, Baris Okcun, İhsan Nuri Akpinar, Melih Hulusi Us, Ger H Koek

   期刊:

   Hepatology international PubMed

   DOI:

   10.1007/s12072-026-11147-8

   日期:

   2026-09-16

   [中文摘要] 代谢功能障碍相关脂肪性肝病（MASLD）与冠状动脉疾病（CAD）具有共同的病理生理通路。然而，不同阶段的MASLD与不同冠状动脉粥样硬化表型之间的关系仍不明确。我们使用配对的振动控制瞬态弹性成像（VCTE）和冠状动脉计算机断层扫描血管造影（CCTA）评估了肝脏脂肪变性和纤维化与冠状动脉疾病结局的关联。共纳入425名在三个月内同时接受VCTE和CCTA检查的成年人。MASLD定义为受控衰减参数（CA…

   查看详情PubMed 原文记录
3. JCR分区: Q1 CAS分区: B1 影响因子: 7.8

   3. How to apply artificial intelligence (AI) to facilitate and enhance MASH trials.

   PMID:

   42749968

   作者:

   Daniel Yan Zheng Lim, Wei Qiang Leow, Daniela S Allende, Wai Kay Seto, Terry Cheuk-Fung Yip, George Boon Bee Goh

   期刊:

   Hepatology international PubMed

   DOI:

   10.1007/s12072-026-11150-z

   日期:

   2026-09-16

   Metabolic dysfunction-associated steatohepatitis (MASH) is one of the most common liver diseases, but thus far only two drugs (resmetirom and semaglutide) have received conditional approval for use. S…

   查看详情PubMed 原文记录
4. JCR分区: Q1 CAS分区: B1 影响因子: 7.8

   4. Noninvasive surrogate endpoints in MASH trials: current perspectives and challenges.

   PMID:

   42732486

   作者:

   Hye Won Lee, Luis Antonio Díaz, Vincent Wai-Sun Wong, Wah Kheong Chan

   期刊:

   Hepatology international PubMed

   DOI:

   10.1007/s12072-026-11148-7

   日期:

   2026-09-13

   Metabolic dysfunction-associated steatohepatitis (MASH) is a leading cause of cirrhosis and liver-related morbidity. Current regulatory pathways rely on histology and long-term clinical outcomes, but …

   查看详情PubMed 原文记录
5. JCR分区: Q1 CAS分区: B1 影响因子: 7.8

   5. Antiviral therapies are associated with reduced mortality but under-utilized in patients with viral hepatocellular carcinoma: a multinational REAL-HCC study.

   5. 抗病毒治疗与病毒性肝细胞癌患者死亡率降低相关但未得到充分利用：一项跨国REAL-HCC研究

   PMID:

   42728539

   作者:

   Taotao Yan, Pei-Chien Tsai, Ming-Lun Yeh, Dae Won Jun, Hidenori Toyoda, Yao-Chun Hsu, Jennifer Leong, Xiaozhong Wang, Xu Qiang, Hiroshi Abe, Takanori Suzuki, Chia-Yen Dai, Jee-Fu Huang, Wan-Long Chuang, Chung-Feng Huang, Yao-Li Chen, Ping-Yi Lin, Satoshi Yasuda, Joanne Kimiko Liu, Mayumi Maeda, Eiichi Ogawa, Cheng-Hao Tseng, Maria Buti, Philip Vutien, Yu Jun Wong, Huy Trinh, Takashi Honda, Haruki Uojima, Masaru Enomoto, Yasuhito Tanaka, Myron Schwartz, Ramsey Cheung, Ming-Lung Yu, Mindie H Nguyen

   期刊:

   Hepatology international PubMed

   DOI:

   10.1007/s12072-026-11146-9

   日期:

   2026-09-11

   Antiviral treatment can reduce mortality of viral hepatocellular carcinoma (HCC), but may be underutilized. In a multinational real-world consortium of HCC patients with hepatitis B (HBV-HCC) or C (HC…

   查看详情PubMed 原文记录
6. JCR分区: Q1 CAS分区: B1 影响因子: 7.8

   6. Real-world outcomes of lenvatinib versus sorafenib as the second-line therapy after atezolizumab plus bevacizumab in patients with hepatocellular carcinoma: a large-scale multicenter study in Korea.

   PMID:

   42726197

   作者:

   Min Ji Lee, Subin Lim, Jae Yong Shim, Mi Na Kim, DongKyu Kim, Kyu-Pyo Kim, Kang Mo Kim, Baek-Yeol Ryoo, Won-Mook Choi, Hyun-Jeong Kim, Seung-Hoon Lee, Gaeun Kang, Mira Kang, Won Chul Cha, Jung Yong Hong, Woo Kyoung Jeong, Sung Kyung Ju, Jung-Hyun Won, Doik Lee, Jiyoon Ahn, Do Young Kim

   期刊:

   Hepatology international PubMed

   DOI:

   10.1007/s12072-026-11142-z

   日期:

   2026-09-11

   After first‑line atezolizumab plus bevacizumab (ATE + BEV) in hepatocellular carcinoma (HCC), optimal second‑line (2L) therapy remains unclear. This study compared the real‑world effectiveness and hep…

   查看详情PubMed 原文记录
7. JCR分区: Q1 CAS分区: B1 影响因子: 7.8

   7. Alcohol and dementia: is hepatic steatosis an innocent bystander or an active contributor to cognitive decline?

   PMID:

   42714794

   作者:

   Cameron Gofton, Elie Matar, Jacob George

   期刊:

   Hepatology international PubMed

   DOI:

   10.1007/s12072-026-11149-6

   日期:

   2026-09-09

   该文献暂无摘要。

   查看详情PubMed 原文记录
8. JCR分区: Q1 CAS分区: B1 影响因子: 7.8

   8. Contemporary epidemiology and real-world management of hepatocellular carcinoma (HCC) in Australia: insights from a prospective Australian National Clinical Quality Registry.

   PMID:

   42663934

   作者:

   Jonathan Abdelmalak, John S Lubel, Simone Strasser, Usha Kaur Khalsa, Georgia Martin, Wendy Swift, Xuan Wu, Katherine Bateman, Andrew Chan, Avik Majumdar, Marie Sinclair, Anouk Dev, Pohwein Loh, Steven Bollipo, Merlyn Joseph, Leya Nedumannil, Siddharth Sood, Catherine Yu, Stephen Riordan, Donna Zhuang, Edmund Tse, Marnie Wood, Jacinta Holmes, Jessica Howell, Alexander Thompson, Brooke Gaggin, James O'Beirne, William Kemp, Ammar Majeed, Faizah Alam, Myo J Tang, Irene Binu, Namrata Chauhan, Stephanie Elias, Daniel Saitta, Zina Valaydon, Tsz Hong Yiu, Eileen Lam, John R Zalcberg, Stuart K Roberts

   期刊:

   Hepatology international PubMed

   DOI:

   10.1007/s12072-026-11144-x

   日期:

   2026-08-28

   Hepatocellular carcinoma (HCC) is a rapidly increasing healthcare burden in Australia. We aimed to evaluate the contemporary epidemiology, clinical characteristics, and real-world patterns of care for…

   查看详情PubMed 原文记录
9. JCR分区: Q1 CAS分区: B1 影响因子: 7.8

   9. Clonal hematopoiesis of indeterminate potential and metabolic dysfunction-associated steatotic liver disease: Korean biopsy cohort.

   PMID:

   42658470

   作者:

   Yun Kyu Lee, Hyungtai Sim, Sae Kyung Joo, Heejoon Jang, Dong Hyeon Lee, Jeong Hwan Park, Keon Wook Kang, Murim Choi, Won Kim

   期刊:

   Hepatology international PubMed

   DOI:

   10.1007/s12072-026-11143-y

   日期:

   2026-08-27

   Clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a contributor to age-related diseases; however, its clinical relevance to metabolic liver disease remains to be established. This …

   查看详情PubMed 原文记录
10. JCR分区: Q1 CAS分区: B1 影响因子: 7.8

    10. Correction: The Asian Pacific Association of the Study of the Liver expert survey on artificial intelligence-assisted reporting of liver histopathology in metabolic dysfunction associated fatty liver disease.

    PMID:

    42637880

    作者:

    H Elangovan, K Akbary, A Rastogi, A Wee, G Soon, L Adams, E Carr-Boyd, A Clouston, C L Cooper, W K Chan, Y Y Dan, R Dela-Cruz, G Goh, S S Hamid, D Q Huang, T Kawaguchi, H Kim, W Kim, S U Kim, J D Jia, C J Liu, F Liu, W Q Leow, M D Muthiah, I Ng, D Payawal, A F Pan, S Pervez, G Shiha, T Tanwandee, Y Tanaka, L Thiyaphat, M Vij, Y Yilmaz, F Yilmaz, M L Yu, K Zalata, M H Zheng, J G Fan, S K Sarin, V Wong, J George

    期刊:

    Hepatology international PubMed

    DOI:

    10.1007/s12072-026-11131-2

    日期:

    2026-08-24

    该文献暂无摘要。

    查看详情PubMed 原文记录